MDR Acinetobacter Baumannii Antibiotic Utilization and Risk Factors of MDR Acinetobacter Baumannii Infection at Surin Hospital
Article Sidebar
Main Article Content
Abstract
Background: Mutiple drug-resistant gram negative bacilli (MDRGNB) infection leads to limited choice of antibiotic drug therapy. In 2007, it was recognized by Infectious Control committee’s annual report that rate of Acinetobacter baumannii infection had been increasing, The present study was conducted with the primary attention to determine the risk factors associated with MDR Acinetobacter baumannii infection and antibiotic treatment.
Objective: To evaluate antibiotic utilization and investigate for the risk factors associated MDR Acinetobacter baumannii infection at Surin Hospital.
Study design: Descriptive retrospective study
Patient : The patients who acquired A. baumannii during their stay in the hospital
Method: The Clinical and laboratory Data collected from patient’s chart and admitted in Surin Hospital during January 1st to December 31st 2007. Statisical analysis of descriptive data presented in frequency, mean, percentile, standard deviation. Independent t-test and Chi-square test
Result: During the study period, 93 patients who were identified as harboring A. baumannii during their hospital stay, 58.51 percent were male. The mean age was 61+16.23 years. Prolonged hospitalization was the significant risk factors associated with MDR Acinetobacter baumannii infection. (22.54+16.82 days.p-value < 0.05) The most site of infection were pneumonia (51.06%), sepsis (42.55%). Drugs that were frequently used empirically for treatment of MDR Acinetobacter baumannii infection were 3rd generation cephalosporins and penicillins group.The appropriateness of antibiotic use showed that 68.00% of document therapy, Cefoperazone/sulbactam and colistin were frequently used, 32.99% and 6.34% respectively. The mean duration of antibiotic treatment was 8.63±5.69 days. Clinical response rate for these antibiotic use was 48.93%
Conclusion: The present study was performed as an initial investigations into risk factors of MDR A. baumannii infection. So the management staff and health officers must concern for the occurrence of multidrug resistance Acinetobacter baumannii, They should have guideline and evaluate for microorganism infectious control in a hospital and need to reduce the spread of antimicrobial resistance bacterial.
Key words: Multidrug Resistance, MDR, Acinetobacter baumannii, Antibiotic Utilization
Article Details
References
2. Wendt C, Dietze B, Dietz E, Ruden H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol 1997;35:1394-7.
3. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival of Acinetobacter baumanniion dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol 1998;36:1938-41.
4. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens; microbiological, clinical,and epidemiological features. Clin Microbiol Rev 1996;9:148-65.
5. Cisneros JM, Reyes MJ, Pachon J, Becerril B, Caballero FJ, Garcia-Garmendia JL, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996;2:1026-32.
6. คณะกรรมการโครงการเฝ้าระวังเชื้อดื้อยาต้านจุลชีพ ศูนย์เฝ้าระวัง เชื้อดื้อยาต้าน จุลชีพแห่งชาติ กรมวิทยาศาลตรการแพทย์ กระทรวงสาธารณสุข. รายงานการเฝ้าระวัง เชื้อดื้อยาต้านจุลชีพแห่งชาติ. NARST;1-2.
7. คณะกรรมการป้องกันและควบคุมการติดเชื้อในโรงพยาบาล โรงพยาบาลสุรินทร์ กระทรวงสาธารณสุข.รายงานประจำปี 2549-2551.
8. กัลยาณี คุระครางค์และคณะ. ปัจจัยเสี่ยงของการติดเชื้อดื้อยา Acinetobacter baumannii ในโรงพยาบาลศิริราช, J Med Assoc Thai 2007;90(8):1633-9.
9. กนกอร ลีเพชรรัตน์.การติดเชื้อและเชื้อโรค ก่อในตัวของ Acinetobacter baumanniilv, หอผู้ป่วยกุมารเวชศาลตรโรงพยาบาลมหาราชนครเชียงใหม่ในช่วงปี พ.ศ. 25452546 [cited 2008 Sep 10]. Available from : URL https://www.thaipediatrics.org/abstract/24082006/new.doc)
10. ศริพร แซ่เล้า, อัจฉรา อุทิศวรรณกุล. การรักษาผู้ป่วยปอดอักเสบในโรงพยาบาลอันเนื่องมาจากเชื้อดื้อยา Acinetobacter baumannii, J Health Res 2008, 22(3):131-6.
11. The American Thoracic Society and The Infectious Disease Society of America. 2005. Guideline for themanagement of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416
